We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Advances in Liquid Biopsies Improve Detection of Lung Cancer Mutations

By LabMedica International staff writers
Posted on 14 Jan 2026

Lung cancer remains one of the deadliest cancers, largely because diagnosis often occurs at an advanced stage when treatment options are limited. More...

In non-small cell lung cancer (NSCLC), identifying genetic alterations quickly is critical, as several mutations can be targeted with specific therapies that significantly improve survival. Conventional tissue biopsies, however, are invasive and time-consuming, delaying treatment decisions. Researchers have now demonstrated that blood-based testing can detect key lung cancer mutations earlier and more accurately, including in asymptomatic individuals.

In the study conducted at Hospital de Amor de Barretos (São Paulo, Brazil), with support from FAPESP (São Paulo, Brazil), researchers evaluated a commercial multigene liquid biopsy panel designed to detect known mutations associated with lung adenocarcinoma using circulating tumor DNA (ctDNA) extracted from blood samples. The test analyzes mutations across 11 genes involved in tumor development, including clinically actionable targets such as EGFR, ALK, and KRAS. Liquid biopsy allows blood samples to be collected at any time, without the need for invasive procedures, and does not require special collection tubes or immediate processing.

The researchers analyzed 32 plasma samples from 30 individuals, including untreated patients, previously treated patients, and participants enrolled in a lung cancer screening program. Mutations were detected in 65.6% of all samples, rising to 87.5% among patients who had already undergone treatment. The most frequent alterations were found in TP53, KRAS, and EGFR. Notably, an EGFR resistance mutation (p.T790M) was identified, which has direct implications for therapy selection. The study, published in Molecular Oncology, confirms the feasibility and sensitivity of multigene liquid biopsy testing in a real-world Brazilian hospital setting.

One of the most striking findings was the detection of a TP53 mutation in an asymptomatic screening participant six months before a formal lung cancer diagnosis. This highlights the potential role of liquid biopsy as a complementary screening tool for high-risk populations such as smokers and former smokers. In addition to early detection, liquid biopsy can dramatically shorten turnaround time. While tissue biopsy results may take weeks, liquid biopsy results can be available within two days, enabling faster treatment initiation. Researchers suggest that with declining sequencing costs and broader access, this approach could become integrated into routine lung cancer care in Brazil.

“Our work shows that it’s possible to detect several mutations at the same time, reduce response time, and use samples that don’t require special collection,” said Letícia Ferro Leal, researcher and co-supervisor of the study. “This can accelerate the start of treatment and improve patient outcomes, although liquid biopsy should still be used alongside conventional tissue biopsy.”

Related Links:
Hospital de Amor de Barretos
FAPESP


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.